Specialised commissioning in the NHS – how to plan for 2024
What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty? Join Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) and David Thorne (Principal Associate, Mtech Access) as they explore specialised commissioning in the NHS and what to expect as we head into 2024. We will explore: • Specialised commissioning in the NHS • The risks and opportunities devolution to ICBs will bring • What we can expect to see in the short and longer term • How industry can support ICB leaders through this transition • How Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertainties Learn more at: https://mtechaccess.co.uk/nhs-specialised-commissioning/ If you cannot attend the webinar but would like to know more, please register nonetheless, as all registrants will receive a recording of the webinar. The webinar is free and open to all market access, patient access, field-based, and other healthcare professional facing teams in Pharmaceutical and Medtech companies. We also welcome attendees from the NHS. Some colleagues from other organisations may attend, at the discretion of Mtech Access.
